FOUNDER PROFILE

Jose Vidal Obón

Jose Vidal Obón

Jose Vidal Obón

Co-founder, CEO & CFO Spain of Nutrinsect

Jose Vidal Obón is the Spanish-born co-founder, CEO and CFO for Spain of Italo-Spanish insect protein manufacturer Nutrinsect, where he has worked since 2016. He is also on the Spanish board of insurance company AXA. Prior to Nutrinsect, he worked for six years as manager of Madrid-based insurance company Crédito y Caución and for two years as supervisor at Italian bank Banca Mediolanum. Vidal is an economics graduate.  

 

Limited Reading

The rest of the content is only available if you are logged in.

Limited Reading
RELATED INSIGHTS
RECOMMENDED

Founder

Agung Mahesa Yudhistira

Co-founder and UI/UX Manager of Bobobox

Founder

Utari Octavianty

Co-founder and Chief General Affairs Officer of Aruna

Founder

Afrig Wasiso

Vice-President and co-founder of Santara

RELATED INSIGHTS

Gift This Article

The gift link can be opened by one recipient only.

You have 19 gift credits left this month

Your payment was not successful.

Please make sure you have entered your payment details correctly. Or try again in a few moments.

small logo

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download successful.

Your sample has been sent. Please check your email.

By accessing and using www.compasslist.com and all pages within the domain (the “Website”), You accept and agree to have read, understood, accepted and agreed to be bound by the Terms of Use and Privacy Policy in full. If you disagree with all or any part of these Terms of Use and Privacy Policy, please do not use or continue any further use of this website. You acknowledge that you are aware that this Website contains an archive of existing content as at 31 December 2021 and is not being actively managed. We are under no obligation to update the content on this Website and, accordingly, no new content or articles will be posted to the Website after 31 December 2021.